FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections
Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment
Many Breast Cancer Survivors Do Not Undergo Annual Surveillance
In year 1, 13 percent did not undergo MRI or mammography; up to 19 percent by year 5
ASCO: Pembrolizumab Superior for Initial Tx of Advanced NSCLC
Improved overall survival versus chemotherapy regardless of the PD-L1 tumor proportion score
ASCO: mCRC Costs Up in Western Washington vs. British Columbia
No significant difference between regions in median OS for those receiving, not receiving systemic tx
Personalized Therapy Promising in Metastatic Breast Cancer
Adaptive transfer of mutant-protein-specific tumor-infiltrating lymphocytes leads to disease regression
ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
Sunitinib alone noninferior to nephrectomy plus sunitinib with respect to overall survival
ASCO: Endocrine Tx Noninferior for HR+, HER2− Breast Cancer
Similar efficacy for endocrine, chemoendocrine tx for women with midrange 21-gene recurrence score
ASCO: mFOLFIRINOX Improves Survival in Pancreatic Cancer
And, pre-op chemoradiotherapy linked to longer overall survival than immediate surgery
May 2018 Briefing – Hematology & Oncology
Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for May 2018. This roundup includes...
Male Thyroid Cancer Survivors Face Higher CVD Risk
Age at diagnosis, sex, BMI, and thyroid-stimulating hormone suppression therapy affect CVD risk
